Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Aritra Gangopadhyay

Gilead Sciences's Q1 2026 Earnings: What to Expect

Foster City, California-based Gilead Sciences, Inc. (GILD) discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States and internationally. The company has a market cap of $173 billion and provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo for the treatment of HIV-1 infection in patients, as well as other related drugs.

GILD is expected to release its Q1 2026 earnings soon. Ahead of the event, analysts expect the company’s EPS to be $1.86 on a diluted basis, up 2.8% from $1.81 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in three of its last four quarters, while missing the mark once.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.